Scarica l'app Stockscreener
8.225
0.68%
0.475
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.75
Aprire:
$7.86
Volume 24 ore:
1.56M
Relative Volume:
1.41
Capitalizzazione di mercato:
$451.69M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-2.0012
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
+4.60%
1M Prestazione:
+35.94%
6M Prestazione:
+105.88%
1 anno Prestazione:
-32.79%
Intervallo 1D:
$7.74
$8.45
Intervallo di 1 settimana:
$6.93
$8.45
Portata 52W:
$2.10
$12.45
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
8.22 | 375.36M | 3.64M | -87.37M | -86.46M | -4.11 |
|
ONC
Beigene Ltd Adr
|
236.20 | 25.21B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.28 | 112.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.285 | 40.72M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
612.45 | 62.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.64 | 5.75B | 0 | -153.72M | -103.81M | -2.00 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Jefferies | Buy |
| 2025-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Tempus partners with Verastem for companion diagnostic development - Yahoo Finance
Tempus AI teams up with Verastem for companion diagnostic test - Seeking Alpha
Tempus and Verastem partner on ovarian cancer diagnostic test - Investing.com Australia
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment - BioSpace
(VSTM) Investment Analysis - news.stocktradersdaily.com
Verastem (VSTM) Plans to Offer 3.43 Million Shares of Common Sto - GuruFocus
Verastem: Q1 Earnings Snapshot - Greenwich Time
Verastem (VSTM) Advances Pipeline with Key Developments | VSTM S - GuruFocus
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates - BioSpace
Verastem Oncology Reports First Quarter 2025 Financial Results a - GuruFocus
Verastem, Inc. SEC 10-Q Report - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evolent Health (EVH), Verastem (VSTM) and Sight Sciences (SGHT) - The Globe and Mail
Today's Research Reports on Stocks to Watch: Alder BioPharmaceuticals Inc. and Verastem Inc. - ACCESS Newswire
Verastem’s Combination Therapy For Ovarian Cancer Gets FDA Approval: Retail’s Pleased - MSN
Verastem (VSTM) Sees Price Target Increase and FDA Approval Boos - GuruFocus
Verastem (VSTM) Sees Increased Price Target Following FDA Approval | VSTM Stock News - GuruFocus
High-graded low-grade ovarian duo wins for Verastem at FDA - BioWorld MedTech
B. Riley Adjusts Verastem Price Target to $13 From $12, Maintains Buy Rating - marketscreener.com
Mizuho Adjusts Price Target on Verastem to $16 From $8, Maintains Outperform Rating - marketscreener.com
Verastem (VSTM) Stock Update: Analyst Raises Price Target to $14 | VSTM Stock News - GuruFocus
RBC Raises Price Target on Verastem to $16 From $14, Keeps Outperform, Speculative Risk - marketscreener.com
Verastem (VSTM) Price Target Increased by RBC Capital Analyst | VSTM Stock News - GuruFocus
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer - BioSpace
Verastem stock price target raised to $19 by Jefferies - Investing.com Canada
Verastem Gains FDA Approval for New Cancer Treatment - TipRanks
Health Care Stocks See Mixed Results In Market Movements - Finimize
Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer - insights.citeline.com
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare Type of Ovarian Cancer - MedCity News
FDA Approves Avutometinib/Defactinib for Adults With KRAS-Mutated Recurrent LGSOC - Pharmacy Times
US FDA approves Verastem's ovarian cancer therapy - Reuters
FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer - Benzinga
US FDA approves Verastem’s cancer therapy - WHTC
Verastem (VSTM) Gains as Analyst Increases Price Target Following FDA Approval | VSTM Stock News - GuruFocus
Verastem Oncology Cancer Drug Combination Gets FDA Approval - marketscreener.com
FDA grants Verastem first approval for rare ovarian cancer treatment - Endpoints News
Verastem Says AVMAPKI FAKZYNJA Co-Pack Expected To Be Available For Adult Patients In U.S. In One Week - marketscreener.com
FDA Greenlights Verastem's (VSTM) New Cancer Treatment - GuruFocus
Verastem's Avmapki Fakzynja receives FDA accelerated approval for ovarian cancer - Seeking Alpha
U.S. FDA approves Verastem's cancer therapy - marketscreener.com
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo - GuruFocus
FDA Grants Approval for Verastem's (VSTM) Cancer Treatment Combo | VSTM Stock News - GuruFocus
Trading (VSTM) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
B. Riley Issues Pessimistic Outlook for Verastem Earnings - Defense World
Verastem (VSTM) Schedules Conference Call with Key Executives | - GuruFocus
Verastem Oncology to Present at Upcoming Investor Conferences | - GuruFocus
Ovarian Cancer Market: Epidemiology, Therapies, Companies, - openPR.com
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.44%
2.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):